awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33754114-4ED8008A-1071-4883-B78E-C817B269A174
Q33754114-4ED8008A-1071-4883-B78E-C817B269A174
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33754114-4ED8008A-1071-4883-B78E-C817B269A174
The new concepts on overcoming drug resistance in lung cancer.
P2860
Q33754114-4ED8008A-1071-4883-B78E-C817B269A174
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33754114-4ED8008A-1071-4883-B78E-C817B269A174
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
72458e6173ce1822107492c03b71f984ba22400f
P2860
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.